



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

June 15, 2023

Lara Sullivan, M.D.
Chief Executive Officer
Pyxis Oncology, Inc.
321 Harrison Avenue
Boston, MA 02118

Re: Pyxis Oncology, Inc.
Registration Statement on Form S-4
Filed June 8, 2023
File No. 333-272510

Dear Lara Sullivan:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dillon Hagius at 202-551-7967 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Istvan A. Hajdu